# AstraZeneca Posts $16.21 Billion in Q3 Revenue, Reaffirms 2026 Outlook By John Kim Canonical URL: https://www.tokenpost.com/news/business/44452 Published: 2026-10-30T09:02:35.000Z Updated: 2026-10-30T09:02:35.000Z Section: Business > Revenue rose 7% year over year. The company expects Core EPS to increase by a low double-digit percentage at constant exchange rates. AstraZeneca posted third-quarter revenue of $16.21 billion and reaffirmed its 2026 outlook Friday, as sales climbed 7% year over year and Core EPS reached $2.79. Revenue came to $16.21 billion. Full-year guidance calls for total revenue to grow by a mid- to high-single-digit percentage, while Core EPS is expected to increase by a low double-digit percentage at constant exchange rates. The earlier [earnings preview]() listed a rounded $16 billion consensus estimate for quarterly revenue. ## Links in this article - [earnings preview](https://www.tokenpost.com/news/business/43785)